Valuation: VACY AS

Market Cap 105.15Cr 0 11Cr 9.29Cr 8.58Cr 8Cr 15Cr 1TCr 15Cr 102.88Cr 40Cr 495.26Cr 40Cr 39Cr 1.73TCr P/E 2026 *
-4.98x
P/E 2027 * -34.8x
Enterprise Value 57Cr 0 5.72Cr 5Cr 4.62Cr 4.31Cr 8.12Cr 540.61Cr 8.26Cr 55Cr 22Cr 266.77Cr 21Cr 21Cr 929.36Cr EV / Sales 2026 *
-
EV / Sales 2027 * 2.93x
Free-Float
56.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
President 49 01/01/2017
Chief Executive Officer 54 01/01/2019
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 10Cr
+3.31%+1.93%+69.29%+129.27% 5.58TCr
-1.32%+16.55%+89.14%+101.41% 5.57TCr
-1.28%+2.68%-12.60%-13.79% 2.38TCr
+1.79%+4.38%+5.94%+405.31% 2.27TCr
+4.45%+8.43%+37.08%-29.19% 1.61TCr
+0.24%+5.98%+23.45%+184.72% 1.36TCr
+5.51%+22.37%+171.85%+333.54% 1.48TCr
+1.83%+4.58%+77.42%+132.45% 1.22TCr
-2.37%+6.47%+157.84%+161.16% 1.18TCr
Average +1.22%+6.15%+68.82%+156.10% 2.52TCr
Weighted average by Cap. +1.20%+5.02%+65.91%+142.28%

Financials

2026 *2027 *
Net sales - 16Cr 0 1.63Cr 1.43Cr 1.32Cr 1.23Cr 2.32Cr 154.34Cr 2.36Cr 16Cr 6.14Cr 76Cr 6.13Cr 6Cr 265.33Cr
Net income -21Cr -0 -2.1Cr -1.84Cr -1.7Cr -1.58Cr -2.98Cr -198.44Cr -3.03Cr -20Cr -7.9Cr -98Cr -7.89Cr -7.71Cr -341.14Cr -4.16Cr -0 -41.98L -36.74L -33.92L -31.64L -59.61L -40Cr -60.68L -4.07Cr -1.58Cr -20Cr -1.58Cr -1.54Cr -68Cr
Net Debt -49Cr -0 -4.9Cr -4.29Cr -3.96Cr -3.69Cr -6.95Cr -463.03Cr -7.08Cr -47Cr -18Cr -228.49Cr -18Cr -18Cr -796Cr -58Cr -0 -5.83Cr -5.1Cr -4.71Cr -4.39Cr -8.28Cr -551.23Cr -8.43Cr -57Cr -22Cr -272.01Cr -22Cr -21Cr -947.62Cr
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.220NOK
Average target price
5.000NOK
Spread / Average Target
+55.28%

Quarterly revenue - Rate of surprise